How to conduct integrated pharmaceutical care for patients with hand-foot syndrome associated with chemotherapeutic agents and targeted drugs

Chen, Jiexiu; Wang, Zhuo

doi:10.1177/10781552211009291

Cited by 3 publications

(2 citation statements)

References 75 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dose of capecitabine is determined based on the BSA. These results are therefore consistent with the findings of previous studies that reported the development of HFS as dose dependent [10, 17, 18]. Clinicians thus need to be alert to the fact that HFS is likely to occur in patients receiving high doses of capecitabine, particularly patients with BSA ≥1.68 m 2 .…”

Section: Discussionsupporting

confidence: 91%

Risk Factors of Capecitabine-Induced Hand-Foot Syndrome: A Single-Institution, Retrospective Study

Kanbayashi¹,

Taguchi²,

Ishikawa³

et al. 2023

Oncology

View full text Add to dashboard Cite

Introduction: This retrospective study was conducted to identify risk factors for developing hand-foot syndrome (HFS) and to determine new strategies for improving quality of life (QoL) in patients undergoing chemotherapy. Methods: Between April 2014 and August 2018, we enrolled 165 cancer patients at our outpatient chemotherapy center who were undergoing capecitabine chemotherapy. Variables related to the development of HFS were extracted from the clinical records of patients for use in regression analysis. HFS severity was assessed at the time of completing capecitabine chemotherapy. The degree of HFS was classified in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events version 5. Multivariate ordered logistic regression analysis was performed to identify risk factors for the development of HFS. Results: Risk factors for the development of HFS included concomitant use of a renin angiotensin system (RAS) inhibitor (odds ratio [OR] = 2.85, 95% confidence interval [CI] = 1.20–6.79; P = 0.018), body surface area (BSA) (high) (OR = 12.7, 95%CI = 2.29–70.94; P = 0.004) and albumin (low) (OR = 0.44, 95%CI = 0.20–0.96; P = 0.040). Discussion/Conclusion: Concomitant use of RAS inhibitor, high BSA, and low albumin were identified as risk factors for the development of HFS. The identification of potential risk factors of HFS may assist in the development of strategies that can be used to improve QoL in patients receiving chemotherapy regimens that include capecitabine.

show abstract

Section: Discussionsupporting

confidence: 91%

Risk Factors of Capecitabine-Induced Hand-Foot Syndrome: A Single-Institution, Retrospective Study

Kanbayashi¹,

Taguchi²,

Ishikawa³

et al. 2023

Oncology

View full text Add to dashboard Cite

show abstract

“…According to the timeline view and the top 25 most cited keywords in publications exported by CiteSpace V (version5.8 R3), it can be seen that in the past few years, there has been a certain research foundation for targeted therapy-related cutaneous adverse events (AEs): Hand-foot-skin reaction (HFSR), in particular, is one of the most common targeted therapy-induced AEs, will lead to treatment interruption or failure. Some achievements have been made in the diagnosis, prevention, evaluation, management and possible mechanism of HFSR (17)(18)(19)(20)(21)(22). At the same time, four potential research hotspots and frontiers can also be predicted, as follows:…”

Section: Discussionmentioning

confidence: 99%

Global research trends on precision cancer medicine-related rashes (2008-2021): A bibliographic study

Zhao

Chen

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

BackgroundPrecision cancer medicine-related rashes are a kind of skin and mucous lesions caused by precision therapy. More and more evidences indicated that such events should not be ignored in the course of anti-tumor therapy. Since cancer treatment entered the “Precision Era”, there has been a rapid increase in this field. However, there was few bibliometric studies to provide an overall review of this field. This study aims to evaluate the literature output and trends in researches on precision cancer medicine-related rashes from a global perspective.MethodsCollected publications on precision cancer medicine-related rashes from the Web of Science Core Collection database, which were limited to articles and reviews in English. Microsoft Excel, VOS viewer and CiteSpace V were used for quantitative and visual analysis.ResultsA total of 1,229 papers were identified. From 2008 to 2021, annual publications increased year by year. The United States published the most papers in this field (44.9%) and ranking first in citation frequency (19,854 times) and H-index (69). The University of Texas system ranks first with 98 papers published. Lacouture M.E and Robert C were the principal investigators. Cancers has the largest number of articles published, with 70 articles. In recent years, there have been research hotspots related to immunotherapy, including ipilimumab, immunotherapy, tumor microenvironment, association, checkpoint inhibitor, and cutaneous adverse event.ConclusionPrecision cancer medicine-related rashes are a hot research topic in oncology. The number of relevant publications will increase dramatically. “Checkpoint inhibitors”, “skin adverse events”, “associations” and “tumor microenvironment” may become research hotspots in the future.

show abstract

The efficacy and adverse events of regorafenib in advanced gastrointestinal stromal tumors after imatinib and sunitinib failure: a systemic review and meta-analysis

Zhao

Zhang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Regorafenib is an oral tyrosine kinase inhibitor (TKI) approved for the treatment of advanced gastrointestinal stromal tumors (GISTs) previously treated with imatinib and sunitinib. Objective The systematic review and meta-analysis aim to quantify the efficacy and adverse events of regorafenib for patients with advanced GISTs. Methods Based on predetermined selection criteria, we looked through the PubMed, Embase, and Cochrane databases from establishment until September 2022 to identify pertinent papers. Combined percentages were presented as risk ratios (95% confidence intervals) using Stata 17.0 and the Review Manager 5.3. Results Following the screening and quality evaluation, eleven studies were included, two randomized controlled trials and nine non-randomized prospective or retrospective review articles of intervention, involving 768 patients, 400 of whom were male. This meta-analysis showed that the pooled mPFS was 7.18 (95%CI, 5.87–8.50; Z = 10.68, p < 0.001) and the pooled mOS was 19.67 months (95%CI, 11.32–28.03; Z = 4.61, p < 0.001) in patients after receiving regorafenib treatment, which was administered following failure with imatinib and sunitinib therapies. The combined analysis of the studies revealed that the incidence of any grade toxicities associated with regorafenib treatment of GISTs was 97% (95%CI, 0.96–0.98; Z = 144.09, p < 0.001). Regarding specific AEs, the most common AE was hand-foot syndrome (77%, 95%CI, 0.66–0.88; Z = 14.00, p < 0.001), followed by fatigue (55%, 95%CI, 0.41–0.69; Z = 7.83, p < 0.001), hypertension (53%, 95%CI, 0.34–0.72; Z = 5.56, p < 0.001), anemia (53%, 95%CI, 0.03–1.03; Z = 2.06, p = 0.04), thrombocytopenia (53%, 95%CI, 0.02–1.04; Z = 2.02, p = 0.04), liver damage (52%, 95%CI, 0.30–0.74; Z = 4.64, p < 0.001), diarrhea (43%, 95%CI, 0.33–0.53; Z = 8.40, p < 0.001) and hypophosphatemia (42%, 95%CI, 0.30–0.54; Z = 6.98, p < 0.001), hoarseness (34%, 95%CI, 0.18–0.51; Z = 4.06, p < 0.001), oral mucositis (31%, 95%CI, 0.21–0.41; Z = 5.96, p < 0.001), hypothyroidism (30%, 95%CI, 0.12–0.48; Z = 3.22, p < 0.001), eta. In addition, the pooled analysis of the studies revealed that grade3-4 toxicities rate was 59% (95%CI, 0.52–0.66; Z = 16.38, p < 0.001), among which the incidence of hand-foot syndrome, hypertension and hypophosphatemia was 20% (95%CI, 0.16–0.24; Z = 13.22, p = 0.15), 16% (95%CI, 0.10–0.22; Z = 30.62, p < 0.001) and 13% (95%CI, 0.05–0.22; Z = 0.13, p = 0.72). Conclusion The efficacy and adverse events of regorafenib in advanced GISTs after imatinib and sunitinib failure in the present study was similar with demonstrated in other tumors in real-world practice settings. The incidence of several common AEs for regorafenib was lower in our analysis than previously reported, probably due to the fact that adverse events in the included studies involved a lower than the recommended daily dose of 160 mg.

show abstract

How to conduct integrated pharmaceutical care for patients with hand-foot syndrome associated with chemotherapeutic agents and targeted drugs

Cited by 3 publications

References 75 publications

Risk Factors of Capecitabine-Induced Hand-Foot Syndrome: A Single-Institution, Retrospective Study

Risk Factors of Capecitabine-Induced Hand-Foot Syndrome: A Single-Institution, Retrospective Study

Global research trends on precision cancer medicine-related rashes (2008-2021): A bibliographic study

The efficacy and adverse events of regorafenib in advanced gastrointestinal stromal tumors after imatinib and sunitinib failure: a systemic review and meta-analysis

Contact Info

Product

Resources

About